Ads
related to: camp4 therapeutics corp ipo schedule today liveworkiva.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
CRISPR Therapeutics recently hit a breakthrough point when it earned approval for its first product, Casgevy, a therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
The stock has gained nearly 200% since. INSTACART: The San Francisco-based company, which is incorporated as Maplebear Inc, was priced at the top end of the marketed range in its IPO. It raised ...
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and ...
An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors [1] and usually also to retail (individual) investors. [2] An IPO is typically underwritten by one or more investment banks, who also arrange for the shares to be listed on one or more stock exchanges.
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
After having been a director since December 2019, Duggan was appointed as CEO of Summit Therapeutics, a clinical-stage drug development company focused on new mechanism antibiotics, in spring 2020. [40] He is the company's leading shareholder and its CEO. [40] Summit is focused on developing ridinilazole, a potential new treatment for C ...
Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...
Ad
related to: camp4 therapeutics corp ipo schedule today live